In recent decades, bacteria’s therapeutic role has aroused attention in medicinal and pharmaceutical research. While bacteria are considered among the primary agents for causing cancer, recent research has shown intriguing results suggesting that bacteria can be effective agents for cancer treatment – they are the perfect vessels for targeted cancer therapy. Several bacterial strains/species have been discovered to possess inherent oncolytic potentials to invade and colonize solid tumors in vivo. The therapeutic strategy of using bacteria for treating cancer is considered to be effective; however, the severe side effects encountered during the treatment resulted in the abandonment of the therapy. State-of-the-art genetic engineering has been recently applied to bacteria therapy and resulted in a greater efficacy with minimum side effects. In addition, the anti-cancer potential of tumor-targeting bacteria through oral administration circumvents the use of the intravenous route and the associated adverse effects. This review aims to provide a comprehensive summary of the latest literature on the role of bacteria in cancer treatment.
Microorganisms have the ability of inhabiting nearly every environment through their sophisticated mechanisms of survival such as biofilm formation and release of outer membrane vesicles (OMVs). The biofilm matrix offers microorganism protection and contributes significantly to several clinical challenges, including symptomatic inflammation, antibiotic resistance, recurrence and the spread of infectious emboli. Moreover, bacteria also have another protective mechanism of vesicle production which is used as a means of disseminating toxins to harm their host. A clear understanding of gene expression switch of bacterium from planktonic to biofilm mode offers clinical potentials in treating bacterial infections. In this respect, the treatment of bacterial infections may be achieved through (1) application of RNA interference technology to silence the expression of proteins involved in the process of biofilm formation, (2) utilization of vesicles in delivering antibiotics and (3) use of natural occurred compounds. In this review, we discuss the relationship between biofilm formation and OMV production with respect to tackling biofilm-related clinical challenges. Some prospective considerations in biofilm-associated infections treatment are also discussed.
20 April 2018 in Journal of Zhejiang University-SCIENCE B
Microorganisms provide both beneficial and harmful effects to human beings. Beneficial effects come from the symbiotic relationship that exists between humans and microbiota, but then several human...
28 August 2023 in Journal of the Science of Food and Agriculture
Pseudomonas aeruginosa is a ubiquitous Gram negative opportunistic pathogen capable of causing severe nosocomial infections in humans, and tobramycin is currently used to treat P. aeruginosa associated lung infections. Quorum sensing regulates biofilm formation which allows the bacterium to result in fatal infections forcing clinicians to extensively use antibiotics to manage its infections leading to emerging multiple drug resistant strains. As a result, tobramycin is also becoming resistant. Despite extensive studies on drug discovery to alleviate microbial drug resistance, the continued microbial evolution has forced researchers to focus on screening various phytochemicals and dietary compounds for antimicrobial potential. Linolenic acid (LNA) is an essential fatty acid that possesses antimicrobial actions on various microorganisms. It was hypothesized that LNA may affect the formation of biofilm on P. aeruginosa and improve the potency of tobramycin. The present study demonstrated that LNA interfered with cell‑to‑cell communication and reduced virulence factor production. It further enhanced the potency of tobramycin and synergistically inhibited biofilm formation through P. aeruginosa quorum sensing systems. Therefore, LNA may be considered as a potential agent for adjunctive therapy and its utilization may decrease tobramycin concentration in combined treatment thereby reducing aminoglycoside adverse effects.